Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 193

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial

Open access
van Poelgeest, Mariette I E, Welters, Marij J P, van Esch, Edith M G, Stynenbosch, Linda F M, Kerpershoek, Gijs, van Persijn van Meerten, Els L, van den Hende, Muriel, Löwik, Margriet J G, Berends-van der Meer, Dorien M A, Fathers, Lorraine M, Valentijn, A Rob P M, Oostendorp, Jaap, Fleuren, Gert Jan, Melief, Cornelis J M, Kenter, Gemma G, van der Burg, Sjoerd H · 2013 · Journal of Translational Medicine

Abstract

Background: Human papilloma virus type 16 (HPV16)-induced gynecological cancers, in particular cervical cancers, are found in many women worldwide. The HPV16 encoded oncoproteins E6 and E7 are tumor-specific targets for the adaptive immune system permitting the development of an HPV16-synthetic long peptide (SLP) vaccine with an excellent treatment profile in animal models. Here, we determined the toxicity, safety, immunogenicity and efficacy of the HPV16 SLP vaccine in patients with advanced or recurrent HPV16-induced gynecological carcinoma. Methods: Patients with HPV16-positive advanced or recurrent gynecological carcinoma (n = 20) were subcutaneously vaccinated with an HPV16-SLP vaccine consisting of a mix of 13 HPV16 E6 and HPV16 E7 overlapping long peptides in Montanide ISA-51 adjuvant. The primary endpoints were safety, toxicity and tumor regression as determined by RECIST. In addition, the vaccine-induced T-cell response was assessed by proliferation and associated cytokine production as well as IFNγ-ELISPOT. Results: No systemic toxicity beyond CTCAE grade II was observed. In a few patients transient flu-like symptoms were observed. In 9 out of 16 tested patients vaccine-induced HPV16-specific proliferative responses were detected which were associated with the production of IFNγ, TNFα, IL-5 and/or IL-10. ELISPOT analysis revealed a vaccine-induced immune response in 11 of the 13 tested patients. The capacity to respond to the vaccine was positively correlated to the patient’s immune status as reflected by their response to common recall antigens at the start of the trial. Median survival was 12.6 ± 9.1 months. No regression of tumors was observed among the 12 evaluable patients. Nineteen patients died of progressive disease. Conclusions: The HPV16-SLP vaccine was well tolerated and induced a broad IFNγ-associated T-cell response in patients with advanced or recurrent HPV16-induced gynecological carcinoma but neither induced tumor regression nor prevented progressive disease. We, therefore, plan to use this vaccine in combination with chemotherapy and immunomodulation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1479-5876-11-88

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 193

Metadata

Authors
van Poelgeest, M. I. E., Welters, M. J. P., van Esch, E. M. G., Stynenbosch, L. F. M., Kerpershoek, G., van Persijn van Meerten, E. L., van den Hende, M., Löwik, M. J. G., Berends-van der Meer, D. M. A., Fathers, L. M., Valentijn, A. R. P. M., Oostendorp, J., Fleuren, G. J., Melief, C. J. M., Kenter, G. G., & van der Burg, S. H.
Venue
Journal of Translational Medicine
Published
2013-04-04
Volume
11
Issue
1
Pages
88-88
ISSN
1479-5876 (ISSN-L)
OpenAlex
W2152517822
Cited by
193
References
5
FWCI
8.34
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. https://app.cochat.ai/papers/10.1186/1479-5876-11-88
The paper
van Poelgeest, M. I. E., Welters, M. J. P., van Esch, E. M. G., Stynenbosch, L. F. M., Kerpershoek, G., van Persijn van Meerten, E. L., van den Hende, M., Löwik, M. J. G., Berends-van der Meer, D. M. A., Fathers, L. M., Valentijn, A. R. P. M., Oostendorp, J., Fleuren, G. J., Melief, C. J. M., Kenter, G. G., & van der Burg, S. H. (2013). HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. Journal of Translational Medicine. https://doi.org/10.1186/1479-5876-11-88

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.